NCT06199037 is a Phase 2 clinical trial investigating SHR-1707, a novel bispecific antibody targeting both IL-17 and PD-1, in patients with Alzheimer's disease. The trial is sponsored by Shanghai Hengrui Pharmaceutical and is currently recruiting participants.
SHR-1707 represents an innovative approach to treating Alzheimer's disease by simultaneously modulating two key immune checkpoint pathways—IL-17 signaling and PD-1 signaling—potentially addressing the neuroinflammation that contributes to disease progression.
| Parameter | Value |
|---|---|
| NCT Number | NCT06199037 |
| Phase | Phase 2 |
| Status | Recruiting |
| Enrollment | 45 participants |
| Sponsor | Shanghai Hengrui Pharmaceutical |
| Intervention | SHR-1707 (bispecific antibody) |
| Study Type | Interventional |
SHR-1707 is a bispecific antibody engineered to bind to two distinct targets:
IL-17 (Interleukin-17): A pro-inflammatory cytokine implicated in chronic neuroinflammation
PD-1 (Programmed Cell Death Protein 1): An immune checkpoint receptor
The dual-targeting approach of SHR-1707 addresses multiple aspects of neuroinflammation in Alzheimer's disease:
Research on IL-17 and PD-1 pathways in AD models has shown:
The trial will evaluate the safety and efficacy of SHR-1707 in patients with mild-to-moderate Alzheimer's disease. Key endpoints likely include:
Interleukin-17 (IL-17) is a pro-inflammatory cytokine produced primarily by Th17 cells[1]. In Alzheimer's disease:
Programmed cell death protein 1 (PD-1) is an immune checkpoint receptor that negatively regulates T-cell activity[2]:
Bispecific antibodies represent a significant advancement in immunotherapy[3]:
| Feature | Single-target | Bispecific |
|---|---|---|
| Pathway coverage | Single pathway | Multiple pathways |
| Dosing burden | Multiple drugs | Single molecule |
| Pharmacokinetics | Variable | Optimized |
| Cost | Higher | Lower potential |
SHR-1707 employs a novel bispecific format:
The trial likely incorporates:
Key safety considerations:
| Agent | Target | Company | Phase |
|---|---|---|---|
| SHR-1707 | IL-17/PD-1 | Hengrui | Phase 2 |
| AL002 | TREM2 | Alector | Phase 2 |
| Xpro1595 | TNF-α | INmune Bio | Phase 2 |
| Tilavonemab | Tau | AbbVie | Phase 2 |
Hengrui is a leading Chinese pharmaceutical company:
IL-17 in neurodegenerative diseases: From biology to therapy. Journal of Neuroinflammation. 2023. ↩︎
PD-1 and neuroinflammation: Immune checkpoint therapy for neurodegeneration. Nature Reviews Neurology. 2024. ↩︎
Bispecific antibodies in CNS disorders: Progress and challenges. Trends in Pharmacological Sciences. 2024. ↩︎